We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. 89bio, Inc. is one of them. 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and cardiometabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, pegozafermin, is a long-acting FGF21 analog designed to treat moderate to severe MASH, including advanced fibrosis, as well as related metabolic disorders. In ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating 89bio, Inc. (NASDAQ: ETNB) related to its sale to Roche Holdings, Inc. Under the terms of ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Last week, Seeking Alpha posted some takes on potential buyouts in the biotech/biopharma sector. Thursday morning, Roche ( OTCQX:RHHBY ) announced it was acquiring 89bio, Inc ( ETNB ) in a deal that could reach $3.5 billion, which inclu ...

收购交易结构 - 罗氏控股公司拟以每股14.50美元现金收购89bio公司全部股份 [1] - 交易额外包含每股最高6美元的非交易型或有价值权利支付 [1] - 总对价包含现金与或有支付两部分构成 [1] 交易调查动态 - 前路易斯安那州总检察长联合KSF律师事务所对收购案展开调查 [1] - 调查针对罗氏控股公司与89bio公司之间的交易条款 [1] - 调查主体为纳斯达克上市公司89bio(代码:ETNB)与场外交易市场罗氏(代码:RHHBY) [1]

We recently published 10 Stocks Stole the Show, 5 Hit Historic Highs. 89bio Inc. (NASDAQ:ETNB) is one of the best performers on Thursday. Shares of 89bio surged to a fresh record high on Thursday as investor funds poured into its stock following announcements that it was set to be acquired by Swiss company Roche for $3.5 billion. At intra-day trading, 89bio Inc. (NASDAQ:ETNB) soared by as much as 86 percent to its highest 52-week price of $15.06, before trimming gains to end the day just up by 85.15 perc ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.BMO Capital analyst Fadi Chamoun downgraded United Parcel Service, Inc. UPS from Outperform to Market Perform and cut the price target from $125 to $96. United Parcel Service shares closed at $85.05 on Thursday. See how other analysts view this stock.HC Wainwright & Co. analyst Andrew S. Fein downgraded the r ...

U.S. stock index futures are showing a mixed performance this Friday morning, September 19, 2025, as investors digest a recent Federal Reserve interest rate cut and look ahead to upcoming economic data. After major indexes closed at record highs on Thursday, premarket trading suggests a cautious start to the day, with S&P 500 (SPX), Nasdaq 100 (US100:IND), and Dow Jones Industrial Average (INDU) futures experiencing slight fluctuations. This follows a period of robust gains driven by optimism surrounding mo ...

主要股指表现 - 标普500指数上涨0.48% 纳斯达克100指数上涨0.95% 道琼斯工业指数上涨0.27% 三大指数均创历史新高[1][2] - 九月E-mini标普期货上涨0.50% E-mini纳斯达克期货上涨0.92%[1] 半导体行业动态 - 英特尔股价大涨超过22% 英伟达同意投资50亿美元并宣布将共同开发PC和数据中心芯片[2][12] - KLA Corp上涨超过6% ASML Holding NV上涨超过6% Applied Materials上涨超过6%[12] - 美光科技上涨超过5% Marvell Technology上涨超过5% ON Semiconductor上涨超过4%[12] - 英伟达股价上涨超过3% GlobalFoundries上涨超过2% NXP Semiconductors NV上涨超过2%[12] - ARM Holdings下跌超过4% 因英伟达投资英特尔的消息影响[17] 宏观经济数据 - 每周初请失业金人数下降33,000人至231,000人 低于预期的240,000人[5] - 九月费城联储商业展望调查上升23.5点至23.2 创8个月新高 远高于预期的1.7[5] - 八月领先指标下降0.5% 差于预期的下降0.2% 为四个月最大降幅[6] - 10年期国债收益率上升1.4个基点至4.101% 创两周新高[7] 个股表现 - CrowdStrike上涨超过12% 公司在投资者简报中讨论AI战略并给出2027财年初步展望[13] - 89bio上涨超过85% 罗氏宣布以35亿美元收购公司 每股收购价14.50美元[13] - AeroVironment上涨超过4% 美国银行首次覆盖给予买入评级 目标价300美元[13] - Allstate上涨超过4% 报告八月灾难损失1.68亿美元 环比下降8.7%[14] - Cooper Cos上涨超过4% 董事会批准增加10亿美元股票回购计划至20亿美元[14] - CSX Corp上涨超过2% RBC资本市场将评级从行业表现上调至跑赢大盘 目标价39美元[14] - FactSet Research Systems下跌超过10% 第四季度调整后EPS为4.05美元低于预期的4.15美元[15] - Red Cat下跌超过10% 宣布计划通过承销公开发行出售普通股[16] - Darden Restaurants下跌超过7% 预测2026年调整后EPS为10.50-10.70美元 中点低于预期的10.67美元[16] - Cracker Barrel下跌超过7% 预测2025年收入33.5-34.5亿美元 低于预期的35.2亿美元[17] - Nucor下跌超过5% 预测第三季度EPS为2.05-2.15美元 远低于预期的2.59美元[17] - Live Nation Entertainment下跌超过2% 遭美国联邦贸易委员会和七个州起诉[18] 央行政策与利率 - 市场定价显示94%概率美联储在10月28-29日FOMC会议上降息25个基点[6] - 英国央行以7-2投票维持官方银行利率在4.00%不变[11] - 掉期市场定价显示ECB在10月30日政策会议上降息25个基点的概率为2%[11] - 10年期德国国债收益率上升5.1个基点至2.726% 创两周新高[10] - 10年期英国国债收益率上升5.1个基点至4.676% 创1.5周新高[10] 国际市场表现 - 欧洲斯托克50指数上涨1.62% 创3.5周新高[6] - 中国上证综指下跌1.15% 从10年高点回落[6] - 日经225指数上涨1.15% 创历史新高[6]

收购交易核心条款 - 罗氏以35亿美元收购89bio 交易预计2025年第四季度完成 [1][2] - 收购对价包含每股14.5美元现金 股权价值约24亿美元 另附最高每股6美元的或有价值权 [3][4] - 若全部里程碑达成 89bio股东将额外获得约10亿美元现金 总溢价达60日均价的52% [4][5] 标的资产技术价值 - 核心资产pegozafermin为FGF21类似物 针对F2-F4阶段MASH患者开展三期临床 [2][6] - 该药物采用独特作用机制 具备与肠促胰岛素药物联合开发的协同潜力 [6] - MASH作为肥胖常见并发症 有望为罗氏带来重大收入机会 [7] 战略布局深化 - 此次收购强化罗氏在心血管、肾脏及代谢疾病领域的产品组合 [1][6] - 公司近期通过收购Carmot Therapeutics获得三个肥胖/糖尿病临床阶段资产 [10] - 与Zealand Pharma合作开发减肥药物petrelintide 进一步拓展肥胖治疗领域 [9] 行业并购趋势 - 2025年医药行业并购活动显著加速 打破2024年低迷态势 [10] - 诺华制药14亿美元收购Tourmaline Bio 获得心血管三期候选药物pacibekitug [11] - 诺华6月以8亿美元收购Regulus Therapeutics 葛兰素史克7月收购efimosfermin alfa拓展肝病管线 [12][13]

On Thursday, Roche Holdings AG RHHBY agreed to acquire 89bio, Inc. ETNB for $2.4 billion. 89Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for liver and cardiometabolic diseases.Roche will acquire the company for $14.50 per share, representing a premium of approximately 79% to 89bio’s closing stock price on September 17, 2025, the last trading day before the announcement of the transaction, and a premium of 52% to 89bio’s 60-day volume-weighte ...